Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Cagri Peptide Research Amylin Analog RUO USA Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit : Benefits: Appetite Suppression Weight Loss Enhanced Satiety Improved Glycemic Control Perfect Combo: When paired with GLP Cagrilintide 10mg CAS 14154556 99 3 STATPeptides Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet